Viridian Therapeutics, Inc.\DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Viridian Therapeutics, Inc.\DE profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Viridian Therapeutics, Inc.\DE's profit margin for the twelve months ending Jun 30, 2026 was -544.1%. For fiscal 2025 it was -483.6%, against -89387.1% the year before. The highest annual figure on record is -39.3% in fiscal 2013.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -483.6% | +88903.5 |
| FY2024 | Dec 31, 2024 | -89387.1% | −13675.6 |
| FY2023 | Dec 31, 2023 | -75711.5% | −68382.2 |
| FY2022 | Dec 31, 2022 | -7329.2% | −4649.1 |
| FY2021 | Dec 31, 2021 | -2680.2% | +7864.1 |
| FY2020 | Dec 31, 2020 | -10544.3% | −9605.6 |
| FY2019 | Dec 31, 2019 | -938.6% | −548.7 |
| FY2018 | Dec 31, 2018 | -390.0% | +272.3 |
| FY2017 | Dec 31, 2017 | -662.3% | −165.5 |
| FY2016 | Dec 31, 2016 | -496.8% | −50.5 |
| FY2015 | Dec 31, 2015 | -446.3% | −324.7 |
| FY2014 | Dec 31, 2014 | -121.7% | −82.3 |
| FY2013 | Dec 31, 2013 | -39.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -44760.2% | +89553.1 |
| Q1 FY2026 | Mar 31, 2026 | -74397.9% | +46313.2 |
| Q4 FY2025 | Dec 31, 2025 | -91178.0% | +19551.1 |
| Q3 FY2025 | Sep 30, 2025 | -49.0% | +89124.2 |
| Q2 FY2025 | Jun 30, 2025 | -134313.3% | −44045.3 |
| Q1 FY2025 | Mar 31, 2025 | -120711.1% | −53291.7 |
| Q4 FY2024 | Dec 31, 2024 | -110729.2% | −17868.1 |
| Q3 FY2024 | Sep 30, 2024 | -89173.3% | −22978.8 |
| Q2 FY2024 | Jun 30, 2024 | -90268.1% | −13791.7 |
| Q1 FY2024 | Mar 31, 2024 | -67419.4% | +2122.4 |
| Q4 FY2023 | Dec 31, 2023 | -92861.1% | −49256.3 |
| Q3 FY2023 | Sep 30, 2023 | -66194.4% | −63775.6 |
| Q2 FY2023 | Jun 30, 2023 | -76476.4% | −64956.5 |
| Q1 FY2023 | Mar 31, 2023 | -69541.8% | −57646.9 |
| Q4 FY2022 | Dec 31, 2022 | -43604.8% | −30078.6 |
| Q3 FY2022 | Sep 30, 2022 | -2418.8% | +4332.6 |
| Q2 FY2022 | Jun 30, 2022 | -11519.9% | −9871.8 |
| Q1 FY2022 | Mar 31, 2022 | -11894.9% | −10622.7 |
| Q4 FY2021 | Dec 31, 2021 | -13526.2% | +154514.6 |
| Q3 FY2021 | Sep 30, 2021 | -6751.4% | −2921.1 |
| Q2 FY2021 | Jun 30, 2021 | -1648.1% | −676.6 |
| Q1 FY2021 | Mar 31, 2021 | -1272.2% | −122.5 |
| Q4 FY2020 | Dec 31, 2020 | -168040.7% | −166424.9 |
| Q2 FY2020 | Jun 30, 2020 | -3830.4% | −3476.5 |
| Q1 FY2020 | Mar 31, 2020 | -971.5% | +2154.6 |
| Q4 FY2019 | Dec 31, 2019 | -1149.8% | +1017.7 |
| Q3 FY2019 | Sep 30, 2019 | -1615.8% | −661.3 |
| Q2 FY2019 | Jun 30, 2019 | -353.9% | +45.5 |
| Q1 FY2019 | Mar 31, 2019 | -3126.1% | −3028.6 |
| Q4 FY2018 | Dec 31, 2018 | -2167.4% | −1631.7 |
| Q3 FY2018 | Sep 30, 2018 | -954.6% | −596.9 |
| Q2 FY2018 | Jun 30, 2018 | -399.4% | +619.0 |
| Q1 FY2018 | Mar 31, 2018 | -97.4% | +1413.4 |
| Q4 FY2017 | Dec 31, 2017 | -535.7% | +637.9 |
| Q3 FY2017 | Sep 30, 2017 | -357.7% | +86.0 |
| Q2 FY2017 | Jun 30, 2017 | -1018.4% | – |
| Q1 FY2017 | Mar 31, 2017 | -1510.8% | – |
| Q4 FY2016 | Dec 31, 2016 | -1173.7% | – |
| Q3 FY2016 | Sep 30, 2016 | -443.7% | – |
See a number that looks wrong?